GPIbα对存在抗FVIII免疫的血友病A小鼠血小板靶向FVIII基因治疗的影响
该研究在存在抑制物的血友病A小鼠中,用2bF8慢病毒转导GPIbαnull或FVIIInull小鼠的造血干细胞并移植给致死照射的rhF8致敏FVIIInull受体,发现GPIbα不影响血小板FVIII表达、止血效果及抑制物消失半衰期,2bF8基因治疗可恢复止血并诱导免疫耐受。
要点
- GPIbα不影响血小板靶向FVIII基因治疗在存在抑制物的血友病A小鼠中的效果。
- 2bF8基因治疗可恢复存在预存免疫的血友病A小鼠的止血功能。
- 抑制物滴度降至检测不到后,rhF8再攻击未引发记忆免疫应答。
核心结论
- GPIbα对存在抑制物的血友病A小鼠的血小板基因治疗无显著影响。
- 2bF8基因治疗可恢复存在预存免疫的血友病A小鼠的止血并促进免疫耐受。
研究设计与样本
- 用2bF8慢病毒转导GPIbαnull小鼠或rhF8致敏FVIIInull小鼠的造血干细胞,移植入致死照射的rhF8致敏FVIIInull受体。
- 通过流式细胞术、FVIII检测和tail bleeding test进行分析。
主要发现
- 移植后99%的血小板来源于供体。
- 接受2bF8LV转导的Ibnull造血干细胞的F8null小鼠(2bF8-Ibnull/F8null)维持巨血小板减少表型。
- 2bF8-Ibnull/F8null受体的血小板FVIII表达水平与接受2bF8LV转导的F8null造血干细胞的F8null小鼠(2bF8-F8null/F8null)相似。
- tail bleeding test显示2bF8-Ibnull/F8null组剩余血红蛋白水平显著高于F8null对照组,但2bF8-Ibnull/F8null与2bF8-F8null/F8null组间无显著差异。
- 抑制物消失半衰期在2bF8-Ibnull/F8null与2bF8-F8null/F8null组间相当。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Essentials Platelet-specific FVIII gene therapy is effective in hemophilia A mice even with inhibitors. The impact of platelet adherence via VWF/GPIbα binding on platelet gene therapy was investigated. GPIbα does not significantly affect platelet gene therapy of hemophilia A with inhibitors. Platelet gene therapy induces immune tolerance in hemophilia A mice with pre-existing immunity. SUMMARY: Background We have previously demonstrated that von Willebrand factor (VWF) is essential in platelet-specific FVIII (2bF8) gene therapy of hemophilia A (HA) with inhibitory antibodies (inhibitors). At the site of injury, platelet adherence is initiated by VWF binding to the platelet GPIb complex. Objective To investigate the impact of GPIbα on platelet gene therapy of HA with inhibitors. Methods Platelet-FVIII expression was introduced by 2bF8 lentivirus (2bF8LV) transduction of hematopoietic stem cells (HSCs) from GPIbαnull (Ibnull ) mice or rhF8-primed FVIIInull (F8null ) mice followed by transplantation into lethally irradiated rhF8-primed F8null recipients. Animals were analyzed by flow cytometry, FVIII assays and the tail bleeding test. Results After transplantation, 99% of platelets were derived from donors. The macrothrombocytopenia phenotype was maintained in F8null mice that received 2bF8LV-transduced Ibnull HSCs (2bF8-Ibnull /F8null ). The platelet-FVIII expression level in 2bF8-Ibnull /F8null recipients was similar to that obtained from F8null mice that received 2bF8LV-transduced F8null HSCs (2bF8-F8null /F8null ). The tail bleeding test showed that the remaining hemoglobin level in the 2bF8-Ibnull /F8null group was significantly higher than in the F8null control group, but there was no significant difference between the 2bF8-Ibnull /F8null and 2bF8-F8null /F8null groups. The half-life of inhibitor disappearance time was comparable between the 2bF8-Ibnull /F8null and 2bF8-F8null /F8null groups. The rhF8 re-challenge did not elicit a memory immune response once inhibitor titers dropped to undetectable levels after 2bF8 gene therapy. Conclusion GPIbα does not significantly impact platelet gene therapy of HA with inhibitors. 2bF8 gene therapy restores hemostasis and promotes immune tolerance in HA mice with pre-existing immunity.
引用
- Chen J, Schroeder JA, Luo X, et al. The impact of GPIbα on platelet-targeted FVIII gene therapy in hemophilia A mice with pre-existing anti-FVIII immunity. J Thromb Haemost. 2019. PMID: 30609275. doi:10.1111/jth.14379
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。